Note 3 - Acquisitions of Ownership Interests	3 Months Ended
Mar. 31, 2021
Notes to Financial Statements
Cost and Equity Method Investments Disclosure [Text Block]	3. Acquisitions of Ownership Interests The following is a summary of additional deployments during the three month period ended March 31, 2021: During the quarter ended March 31, 2021, Syapse raised $68 million of preferred equity which reduced the Company's ownership interest to approximately 11%. The Company recorded a $7.3 million dilution gain as a result of this transaction, which is included in Equity income (loss), net in the Consolidated Statements of Operation. Syapse drives healthcare transformation through precision medicine, enabling provider systems to improve clinical outcomes, streamline operations, and shift to new payment models. The Company funded an additional $1.0 million of convertible loans to Trice Medical, Inc. The Company had previously deployed an aggregate of $10.8 million. Trice is focused on orthopedic diagnostics using fully integrated camera-enabled technologies to provide clinical solutions to physicians.

Note 3 - Acquisitions of Ownership Interests

3 Months Ended

Mar. 31, 2021

Cost and Equity Method Investments Disclosure [Text Block]

3. Acquisitions of Ownership Interests

The following is a summary of additional deployments during the three month period ended March 31, 2021:

During the quarter ended March 31, 2021, Syapse raised $68 million of preferred equity which reduced the Company's ownership interest to approximately 11%. The Company recorded a $7.3 million dilution gain as a result of this transaction, which is included in Equity income (loss), net in the Consolidated Statements of Operation. Syapse drives healthcare transformation through precision medicine, enabling provider systems to improve clinical outcomes, streamline operations, and shift to new payment models.

The Company funded an additional $1.0 million of convertible loans to Trice Medical, Inc. The Company had previously deployed an aggregate of $10.8 million. Trice is focused on orthopedic diagnostics using fully integrated camera-enabled technologies to provide clinical solutions to physicians.